Covidien Makes Liver Tumor Ablation More Predictable

DUBLIN, Ireland--(BUSINESS WIRE)--Overcoming a significant roadblock to predictable ablation of soft tissue, Covidien plc (NYSE:COV) has unveiled an advanced ablation system that offers physicians predictable results regardless of the target location or tissue type. The Emprint™ Ablation System with Thermosphere™ Technology is designed to precisely heat and destroy diseased soft tissue (including liver, lung and kidney), and non-resectable liver tumors.

Help employers find you! Check out all the jobs and post your resume.